Hospira Plans To Acquire Assets Worth US$200mn From Orchid Pharma

News: US-based drug infusion technology company Hospira is considering to buy a manufacturing unit and a researchand development (R&D) centre from Indian pharmaceutical firm Orchid Chemicals & Pharamaceuticals for a consolidated value of US$200mn. The factory that manufactures active pharmaceutical ingredients (APIs) is situated in the city of Aurangabad in Maharashtra and employs 640 people. The research facility, housing 160 scientists and researchers, is located in the southern city of Chennai. Hospira expects the asset purchase to lower costs, facilitate supply of key antibiotic products and help it in the development of APIs.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Infrastructure
Geography: India, United States

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.